Health
Explainer
FDA Nears Approval for Centanafadine, a First-in-Class, Low-Abuse Potential ADHD Drug
3 sources · 52d ago
Explainer
FDA Approves Kisunla to Slow Cognitive Decline in Early Alzheimer's Patients
3 sources · 52d ago
Cardiovascular Health
FDA Approves First Oral PCSK9 Inhibitor to Treat High Cholesterol
6 sources · 52d ago
More in Health
ExplainerCholesterol Management
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
Clinical Cardiologists 45%Pharmaceutical Innovators 30%Evidence-Based Medicine Advocates 25%
6 sources · 23d ago
ExplainerSleep Medicine
Landmark Approval: Zepbound Becomes First Drug Treatment for Obstructive Sleep Apnea
Sleep Medicine Specialists 40%Patients with OSA 35%Healthcare Payers & Regulators 25%
5 sources · 52d ago
Cholesterol CareMedical Breakthrough
FDA Approves First Oral PCSK9 Inhibitor to Lower Cholesterol, Offering Alternative to Injectables
Cardiologists & Lipid Specialists 40%Patient Advocacy Groups 30%Industry Analysts 30%
7 sources · 42d ago
Menopause TreatmentsMedical Breakthrough
FDA Approves First-in-Class Non-Hormonal Drug, Elinzanetant, for Moderate to Severe Menopausal Hot Flashes
Women's Health Specialists 40%Breast Cancer Advocates 30%Pharmacological Researchers 30%
6 sources · 53d ago
Brain HealthExplainer
WHO: 45% of Dementia Cases Potentially Preventable With New Lifestyle Guidelines
Public Health Officials 35%Clinical Neurologists 35%Preventive Medicine Advocates 30%
5 sources · 43d ago
Longevity ScienceRegulatory Reversal
FDA Reverses Course on Drug Preclusion Rule, Reinstating NMN as a Legal Dietary Supplement
Supplement Industry Advocates 45%Consumer Safety Watchdogs 35%Pharmaceutical Developers 20%
7 sources · 53d ago
Longevity ScienceClinical Trial
Landmark Trial: Daily Multivitamin Slows Biological Aging Markers in Seniors Over Two Years
Preventive Medicine Researchers 40%Longevity Scientists 30%Nutritional Biologists 30%
3 sources · 53d ago
ExplainerGene Therapy
Landmark Trial: Novel Base-Editing Gene Therapy Cures Thalassemia Patients
Clinical Researchers 47%Patient Advocates 29%Biotech Industry Analysts 24%
4 sources · 53d ago
Alzheimer's DiagnosticsExplainer
Landmark Alzheimer's Blood Test Allows Primary Care Doctors to Diagnose With Specialist Accuracy
Clinical Optimists 45%Primary Care Providers 35%Cautious Ethicists 20%
7 sources · 53d ago
ExplainerACA Premiums
Why ACA Marketplace Premiums Are Proposed to Rise 14% in 2026
Consumer Advocates 45%Insurers and Actuaries 35%Fiscal Conservatives 20%
2 sources · 53d ago
Psychiatric GeneticsEvidence Pack
Landmark Genetic Study Finds Schizophrenia and Bipolar Disorder Share 70% of Underlying Risk
Genomic Researchers 40%Clinical Psychiatrists 35%Diagnostic Reformers 25%
4 sources · 53d ago
Prenatal CareExplainer
FDA Clears AI Ultrasound System That Significantly Improves Detection of Fetal Anomalies
Maternal-Fetal Specialists 40%Health Tech Developers 30%Patient Advocates 30%
3 sources · 53d ago
Supplement RegulationPolicy Shift
FDA Signals Major Overhaul of Supplement Law, May Allow Synthetic and Fermented Ingredients
Supplement Industry Advocates 44%Consumer Safety Watchdogs 31%Biotech Innovators 25%
7 sources · 54d ago
ExplainerGlobal Health Policy
The Evidence Debate: Why the WHO's New Traditional Medicine Strategy is Facing Backlash
Evidence-Based Medicine Advocates 40%Public Health Pragmatists 40%Traditional Medicine Practitioners 20%
6 sources · 54d ago
Multiple MyelomaTreatment De-escalation
Landmark Trial Shows Two Years of Myeloma Maintenance Therapy Is As Effective As Indefinite Treatment
Clinical Researchers 50%Patient Advocates 30%Healthcare Economists 20%
6 sources · 54d ago